Learn how even subtle declines in heart function may affect the brain years later, potentially increasing the risk of memory ...

KANSAS CITY, Kan., July 02, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform ...

KANSAS CITY, Kan., June 16, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform ...

FDA declines to approve Cingulate's ADHD treatment over manufacturing issues Drug developer Cingulate said on Tuesday the U.S. Food and Drug Administration declined to approve its ‌treatment for ...

Cingulate said the Food and Drug Administration flagged certain chemistry, manufacturing and controls requests in response to its application for a drug treating ADHD. The Kansas City, Kan., ...

June 2 (Reuters) - Drug developer Cingulate (CING.O), opens new tab said on Tuesday the U.S. Food and Drug Administration declined to approve its ‌treatment for attention deficit hyperactivity ...

KANSAS CITY, Kan., June 02, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to ...

After submitting its timed-release version of a decades-old ADHD drug to the FDA nearly a year ago, Kansas City's Cingulate has suffered a setback in its bid to commercialize its first product. But ...

FDA’s CRL focused on CMC deficiencies, with no objections to clinical safety or efficacy, enabling a resubmission pathway primarily driven by manufacturing remediation. The NDA was accepted in October ...

Cingulate Inc. (NASDAQ:CING) is one of the best NASDAQ growth stocks to buy and hold forever. On March 18, Cingulate reported its financial results for Q4 and the full year 2025, highlighting the ...

Shares of Cingulate fell after the biopharmaceutical company posted a wider-than-expected loss in the fourth quarter. The stock was down 27%, at $8.55, midday Wednesday, but has more than doubled in ...